Product Description: Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase MDM-2 inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research[1][2][3][4].
Applications: Cancer-programmed cell death
Formula: C31H25Cl2FN4O3
References: [1]Gollner Andreas, et al. Preparation of spiroindolepyrrolidinone derivatives for use as MDM2-p53 inhibitors: World Intellectual Property Organization, WO2017060431. 2017-04-13./[2]WHO Drug Information-World Health Organization (WHO)./[3]Hao X, et al. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro Oncol. 2023 May 4;25(5):913-926./[4]Yoo C, et al. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future Oncol. 2024 Jan 12.
CAS Number: 2095116-40-6
Molecular Weight: 591.46
Compound Purity: 99.72
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: E1/E2/E3 Enzyme;MDM-2/p53
Deutsch
English
